+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Real World Evidence (RWE) Solutions Market with COVID-19 Impact Analysis by Component (Dataset, Services), Therapeutic Area (Oncology, Cardiovascular, Neurology), End-user (Pharma, MedTech, Payers, Providers), and Region - Forecast to 2026

  • ID: 5402732
  • Report
  • August 2021
  • Region: Global
  • 210 Pages
  • Markets and Markets
Global RWE Solutions Market Anticipated to Reach $2.3 Billion by 2026, Witnessing a CAGR of 14.4% Over the Forecast Period

FEATURED COMPANIES

  • Aetion
  • Cerner Corporation
  • Cognizant
  • ICON plc
  • Oracle
  • Sciformix

The global RWE solutions market is projected to reach USD 2.3 billion by 2026 from USD 1.2 billion in 2021, at a CAGR of 14.4% during the forecast period.

The rising geriatric population (and the subsequent increase in the prevalence of chronic diseases) is a key factor driving the growth of this market. The shift from volume- to value-based care, delays in drug development (and the subsequent increase in development costs), growth in R&D spending, and support from regulatory bodies for the use of RWE solutions are some of the other major factors that are driving the growth of this market. However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection are restraining the growth of this market.

The Services segment accounted for the largest market share in 2020

Based on component, the market is segmented into data sets and services. In 2020, the services segment accounted for a larger share of 58.8% of the global RWE solutions market. This segment is also estimated to grow at the highest CAGR of 16.0% during the forecast period. The rising need to convert data into actionable evidence, the growing need to reduce drug development delays, and the availability of a large volume of healthcare data are the major factors driving the growth of this market segment.

The Oncology segment accounted for the largest market share in 2020

Based on the therapeutic area, the RWE solutions market is broadly categorized into oncology, neurology, immunology, cardiovascular disease, and other therapeutic areas. The oncology segment accounted for the largest share of 24.8% of the RWE solutions market in 2020. This segment is projected to reach USD 560.5 million by 2026 from USD 285.5 million in 2021, at a CAGR of 14.4% during the forecast period. The large share of this segment can be attributed to the high number of clinical trials conducted for oncology and the rising prevalence of cancer worldwide.

The Pharmaceutical and Medical Device Companies segment accounted for the largest market share in 2020

Based on end-user, the RWE solutions market is broadly segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and other end users (CROs, academic institutions, patient advocacy groups, and health technology assessment agencies). The pharmaceutical & medical device companies segment accounted for the largest share of 46.3% of the RWE solutions market in 2020. This segment is also estimated to grow at the highest CAGR of 16.8% during the forecast period. The large share and high growth of this end-user segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings.

North America was the largest regional market for real world evidence solutions market in 2020

The global RWE solutions market is segmented into five major regions, namely, North America, Europe, the Asia-Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 60.8% of the global market. Factors such as the favorable regulatory environment, the increasing number of payers using RWD, the growing number of RWE service providers, and the increasing number of pharmaceutical companies adopting RWE for drug approval processes are driving the growth of the RWE solutions market in North America. The Asia-Pacific market, however, is estimated to grow at the highest CAGR during the forecast period. The increasing government initiatives for the adoption of RWE studies, the rising burden of chronic diseases, increasing demand for better healthcare services, and the increasing geriatric population are driving the growth of the RWE solutions market in the Asia-Pacific.

Research Coverage

The report analyzes the real world evidence solutions market and aims at estimating the market size and future growth potential of various market segments, based on by component, therapeutic area, end-user and region. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

The prominent players in the RWE solutions market are IQVIA (US), IBM Corporation (US), ICON plc (Ireland), PAREXEL International Corporation (US), PPD, LLC (US), Optum, Inc. (US), Cognizant Technology Solutions Corporation (US), Oracle Corporation (US), SAS Institute Inc. (US), Syneos Health, Inc. (US), Anthem, Inc. (US), Clinigen Group plc (UK), Medpace Holdings Inc. (US), and Flatiron Health, Inc. (US).

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 40%, Tier 2: 35%, and Tier 3: 25%
  • By Designation - C-level: 25%, Director-level: 55%, and Others: 20%
  • By Region - North America: 40%, Europe: 25%, Asia-Pacific: 20%, Latin America: 10%, and the Middle East & Africa: 5%

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the real world evidence solutions market. The report analyzes this market by type of component, therapeutic area, end-user and region.
  • Market Development: Comprehensive information on the lucrative emerging markets, by type of component, therapeutic area, end-user and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the real world evidence solutions market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the real world evidence solutions market.
Frequently Asked Questions about the Global Real World Evidence Solutions Market

What is the estimated value of the Global Real World Evidence Solutions Market?

The Global Real World Evidence Solutions Market was estimated to be valued at €1.20 Billion in 2021.

What is the growth rate of the Global Real World Evidence Solutions Market?

The growth rate of the Global Real World Evidence Solutions Market is 14.4%, with an estimated value of €2.30 Billion by 2026.

What is the forecasted size of the Global Real World Evidence Solutions Market?

The Global Real World Evidence Solutions Market is estimated to be worth €2.30 Billion by 2026.

Who are the key companies in the Global Real World Evidence Solutions Market?

Key companies in the Global Real World Evidence Solutions Market include Aetion, Anthem, Cegedim Health Data, Cerner Corporation, Ciox Health, Clinigen, Cognizant, Flatiron Health and ICON plc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aetion
  • Cerner Corporation
  • Cognizant
  • ICON plc
  • Oracle
  • Sciformix
1 Introduction
1.1 Objectives of the Study
1.2 Market Definition
1.2.1 Inclusions and Exclusions
1.2.2 Markets Covered
1.2.3 Years Considered for the Study
1.3 Currency
Table 1 Exchange Rates Utilized for Conversion to USD
1.4 Limitations
1.5 Stakeholders
1.6 Summary of Changes
2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.1.1 Key Data from Secondary Sources
2.1.2 Primary Data
Figure 2 Primary Sources
2.1.2.1 Key Data from Primary Sources
2.1.2.2 Insights from Primary Experts
Figure 3 Breakdown of Primary Interviews: Supply-Side and Demand-Side Participants
Figure 4 Breakdown of Primary Interviews (Supply Side): by Company Type, Designation, and Region
2.2 Market Size Estimation: RWE Solutions Market
Figure 5 Supply-Side Market Size Estimation: Revenue Share Analysis
Figure 6 CAGR Projections: Overall Real-World Evidence Solutions Market
2.2.1 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
Figure 7 Data Triangulation Methodology
2.4 Market Ranking Analysis
2.5 Assumptions for the Study
2.6 Risk Assessment
Table 2 Risk Assessment: Real-World Evidence Solutions Market
2.7 Limitations
2.7.1 Methodology-Related Limitations
2.7.2 Scope-Related Limitations
3 Executive Summary
Figure 8 Real-World Evidence Solutions Market, by Component, 2021 vs. 2026 (USD Million)
Figure 9 Real-World Evidence Solutions Market, by Therapeutic Area, 2021 vs. 2026 (USD Million)
Figure 10 Real-World Evidence Solutions Market, by End-user, 2021 vs. 2026 (USD Million)
Figure 11 Real-World Evidence Solutions Market: Geographic Snapshot
4 Premium Insights
4.1 Real-World Evidence Solutions Market Overview
Figure 12 Support from Regulatory Bodies for the Use of RWE Solutions is a Major Factor Driving the Market Growth
4.2 Asia-Pacific: Real-World Evidence Solutions Market, by End-user and Country (2020)
Figure 13 Japan Accounted for the Largest Share of the Asia-Pacific Market in 2020
4.3 Real-World Evidence Solutions Market: Geographic Growth Opportunities
Figure 14 China to Register the Highest Growth Rate During the Forecast Period
4.4 Regional Mix: Real-World Evidence Solutions Market (2021-2026)
Figure 15 North America Will Continue to Dominate the Real-World Evidence Solutions Market During the Forecast Period
4.5 Real-World Evidence Solutions Market: Developed vs. Developing Markets
Figure 16 Developing Markets to Register Higher Growth Rates During the Forecast Period
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Table 3 Drivers, Restraints, Opportunities, and Challenges: Impact Analysis
5.2.1 Drivers
5.2.1.1 Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases
Figure 17 Growth in the Geriatric Population, by Region (2015-2050)
5.2.1.2 Shift from Volume- to Value-based Care
5.2.1.3 Potential of RWE in Reducing Drug Development Costs and Expediting the Drug Development Process
5.2.1.4 Growth in R&D Spending
Figure 18 Increasing R&D Spending of Pharma Member Companies, 2010-2018
Figure 19 Active Pharmaceutical Pipeline, 2009-2019
5.2.1.5 Support from Regulatory Bodies for the Use of RWE Solutions
5.2.2 Restraints
5.2.2.1 Reluctance to Rely on Real-World Studies
5.2.3 Opportunities
5.2.3.1 Growth Opportunities in Emerging Markets
5.2.3.2 Rising Focus on End-to-End RWE Services
5.2.4 Challenges
5.2.4.1 Lack of Universally Accepted Methodological Standards and Data Processing Infrastructure
5.2.4.2 Shortage of Skilled Professionals
6 Industry Insights
6.1 Industry Trends
6.1.1 Emerging Role of Wearable Devices
Figure 20 Utilization of Wearables in Clinical Trials, by Therapeutic Area (2019)
6.1.2 Social Media-Sourced RWE
6.1.3 Growing Use of RWD and RWE Across the Pharmaceutical Industry
Figure 21 Recommended Investment Model for RWD and RWE
6.1.4 Internal vs. Outsourced RWE Analytics Approach
Figure 22 Internal vs. Outsourced RWE Analytics Approach
6.1.5 Incorporation of Artificial Intelligence in RWD Management
6.2 Real-World Data Sources
Table 4 Indicative List of National Databases in Developed Countries
6.3 Ecosystem Analysis
Figure 23 Ecosystem Coverage: Parent Market (Healthcare IT Solutions)
Figure 24 Ecosystem Coverage: Real-World Evidence Solutions Market
6.4 COVID-19 Impact on the Real-World Evidence Solutions Market
6.5 Regulatory Recommendations for Real-World Evidence Solutions
6.5.1 North America
6.5.2 Europe
6.5.3 Asia-Pacific
6.6 HCIT Expenditure/Pricing Analysis
6.6.1 North America
Table 5 North America: Healthcare Expenditure, by Country
6.6.2 Europe
6.6.3 Asia-Pacific
Table 6 Japan: Healthcare IT Initiatives and Funding
Table 7 China: Healthcare IT Initiatives and Funding
7 RWE Solutions Market, by Component
7.1 Introduction
Table 8 RWE Solutions Market, by Component, 2019-2026 (USD Million)
7.2 Services
7.2.1 Rising Need to Convert Data into Actionable Evidence to Drive the Demand for RWE Services
Table 9 RWE Services Offered by Key Market Players
Table 10 RWE Services Market, by Country, 2019-2026 (USD Million)
7.3 Data Sets
Table 11 RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 12 RWE Data Sets Market, by Country, 2019-2026 (USD Million)
7.3.1 Clinical Settings Data
7.3.1.1 Increasing Utilization of EHR Data for Trial Recruitment to Fuel the Growth of this Market Segment
Figure 25 US: Office-based Physician EHR Adoption (2004-2017)
Figure 26 US: Hospital EHR Adoption (2007-2018)
Table 13 Clinical Settings Data Set Solutions Offered by Key Market Players
Table 14 RWE Clinical Settings Data Market, by Country, 2019-2026 (USD Million)
7.3.2 Claims Data
7.3.2.1 Growing Need to Understand the Economic Benefits of Drug Reimbursement by Payers to Drive Growth in this Market Segment
Table 15 Claims Data Set Solutions Offered by Key Market Players
Table 16 RWE Claims Data Market, by Country, 2019-2026 (USD Million)
7.3.3 Pharmacy Data
7.3.3.1 Increasing Adoption of e-Prescribing Systems to Drive the Growth of this Market Segment
Figure 27 e-Prescribing Utilization Among Pharmacies and Prescribers in the US (2013-2017)
Table 17 Pharmacy Data Set Solutions Offered by Key Market Players
Table 18 RWE Pharmacy Data Market, by Country, 2019-2026 (USD Million)
7.3.4 Patient-Powered Data
7.3.4.1 Increasing Need to Access Opinions on Diseases and Treatments Across Social Media to Drive the Growth of this Market Segment
Table 19 Patient-Powered Data Set Solutions Offered by Key Market Players
Table 20 RWE Patient-Powered Data Market, by Country, 2019-2026 (USD Million)
8 RWE Solutions Market, by Therapeutic Area
8.1 Introduction
Figure 28 Number of Clinical Trials, by Therapeutic Area, 2010-2017
Table 21 Global Number of Clinical Trials in Different Therapeutic Areas, 2016-2020
Table 22 RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
8.2 Oncology
8.2.1 Growing Number of Clinical Trials Focused on Cancer Treatment to Drive the Growth of this Market Segment
Figure 29 Incidence of All Types of Cancers Worldwide (2018)
Table 23 List of Pipeline Drugs for Oncology (2018)
Table 24 RWE Solutions Market for Oncology, by Country, 2019-2026 (USD Million)
8.3 Cardiovascular Disease
8.3.1 High Prevalence of CVD to Drive the Growth of this Market Segment
Table 25 List of Pipeline Drugs for Cardiovascular Disease (2018)
Table 26 RWE Solutions Market for Cardiovascular Disease, by Country, 2019-2026 (USD Million)
8.4 Neurology
8.4.1 Growing Prevalence of Neurological Disorders to Drive the Growth of this Market Segment
Table 27 RWE Solutions Market for Neurology, by Country, 2019-2026 (USD Million)
8.5 Immunology
8.5.1 Increasing Focus on Developing Innovative Products to Drive the Growth of this Market Segment
Table 28 RWE Solutions Market for Immunology, by Country, 2019-2026 (USD Million)
8.6 Other Therapeutic Areas
Table 29 RWE Solutions Market for Other Therapeutic Areas, by Country, 2019-2026 (USD Million)
9 RWE Solutions Market, by End-user
9.1 Introduction
Table 30 RWE Solutions Market, by End-user, 2019-2026 (USD Million)
9.2 Pharmaceutical & Medical Device Companies
9.2.1 Increasing R&D Expenditure and Robust Pipeline to Drive Market Growth
Figure 30 FDA Phase Transition Success Rates, 2006-2015
Figure 31 Annual Drug Approvals by CDER (FDA), 2009-2018
Figure 32 R&D Spending of Pharma Member Companies, 2011-2018
Table 31 RWE Solutions Market for Pharmaceutical & Medical Device Companies, by Country, 2019-2026 (USD Million)
9.3 Healthcare Payers
9.3.1 Increased Focus on Outcome-based Payment Models to Drive the Demand for RWE Solutions
Table 32 RWE Solutions Market for Healthcare Payers, by Country, 2019-2026 (USD Million)
9.4 Healthcare Providers
9.4.1 Rising Need to Improve the Profitability of Healthcare Operations to Boost the Use of RWE Solutions
Table 33 RWE Solutions Market for Healthcare Providers, by Country, 2019-2026 (USD Million)
9.5 Other End-users
Table 34 RWE Solutions Market for Other End-users, by Country, 2019-2026 (USD Million)
10 RWE Solutions Market, by Region
10.1 Introduction
Table 35 RWE Solutions Market, by Region, 2019-2026 (USD Million)
10.2 North America
Figure 33 North America: RWE Solutions Market Snapshot
Table 36 North America: RWE Solutions Market, by Country, 2019-2026 (USD Million)
Table 37 North America: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 38 North America: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 39 North America: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 40 North America: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.2.1 US
10.2.1.1 The US Holds the Largest Share of the North American Market
Table 41 US: Number of Clinical Trials Started, by Company, 2017
Table 42 US: Macroeconomic Indicators
Table 43 US: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 44 US: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 45 US: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 46 US: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.2.2 Canada
10.2.2.1 Growing Number of Clinical Trials in Canada to Drive Market Growth
Figure 34 Canada: Number of Clinical Trials (2013-2017)
Table 47 Canada: Macroeconomic Indicators
Table 48 Canada: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 49 Canada: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 50 Canada: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 51 Canada: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.3 Europe
Table 52 Europe: RWE Solutions Market, by Country, 2019-2026 (USD Million)
Table 53 Europe: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 54 Europe: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 55 Europe: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 56 Europe: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.3.1 Germany
10.3.1.1 High Pharmaceutical R&D Spending in Germany to Boost the Market Growth
Table 57 Germany: Macroeconomic Indicators
Table 58 Germany: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 59 Germany: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 60 Germany: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 61 Germany: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.3.2 UK
10.3.2.1 The Growing Adoption of HTA in the UK and Favorable Government Initiatives are the Key Factors Supporting Market Growth
Table 62 UK: Macroeconomic Indicators
Table 63 UK: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 64 UK: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 65 UK: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 66 UK: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.3.3 France
10.3.3.1 High Number of Oncology Clinical Trials in France to Drive Market Growth
Table 67 France: Macroeconomic Indicators
Table 68 France: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 69 France: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 70 France: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 71 France: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.3.4 Italy
10.3.4.1 The Demand for RWE in Italy is High due to the Widespread Use of Pay-For-Outcomes and Coverage with Evidence Development
Table 72 Italy: Number of Clinical Trials Started, by Company, 2017
Table 73 Italy: Macroeconomic Indicators
Table 74 Italy: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 75 Italy: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 76 Italy: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 77 Italy: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.3.5 Spain
10.3.5.1 Rising R&D Expenditure to Propel Market Growth in Spain
Table 78 Spain: Macroeconomic Indicators
Table 79 Spain: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 80 Spain: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 81 Spain: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 82 Spain: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.3.6 Rest of Europe
Table 83 RoE: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 84 RoE: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 85 RoE: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 86 RoE: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.4 Asia-Pacific
Figure 35 Asia-Pacific: RWE Solutions Market Snapshot
Table 87 Asia-Pacific: RWE Solutions Market, by Country, 2019-2026 (USD Million)
Table 88 Asia-Pacific: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 89 Asia-Pacific: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 90 Asia-Pacific: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 91 Asia-Pacific: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.4.1 Japan
10.4.1.1 Stringent Regulatory Scenario in Japan to Restrain the Market Growth
Table 92 Japan: Macroeconomic Indicators
Table 93 Japan: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 94 Japan: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 95 Japan: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 96 Japan: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.4.2 China
10.4.2.1 Low Cost of Clinical Trials and Large Pharmaceutical R&D Base in China to Drive Market Growth
Figure 36 China: Adult Wearable Device User Base and Internet Penetration (2015-2019)
Figure 37 China: Number of Observational Studies, 2013-2017
Table 97 China: Macroeconomic Indicators
Table 98 China: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 99 China: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 100 China: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 101 China: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.4.3 Rest of Asia-Pacific
Table 102 RoAPAC: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 103 RoAPAC: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 104 RoAPAC: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 105 RoAPAC: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.5 Latin America
10.5.1 Rising Investments and Healthcare Expenditure Show Potential for Market Growth
Table 106 Latin America: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 107 Latin America: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 108 Latin America: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 109 Latin America: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
10.6 Middle East & Africa
10.6.1 Growing Availability of Funding in the Middle East Indicates Opportunities for Market Growth
Table 110 Middles East & Africa: RWE Solutions Market, by Component, 2019-2026 (USD Million)
Table 111 Middles East & Africa: RWE Data Sets Market, by Type, 2019-2026 (USD Million)
Table 112 Middle East & Africa: RWE Solutions Market, by Therapeutic Area, 2019-2026 (USD Million)
Table 113 Middle East & Africa: RWE Solutions Market, by End-user, 2019-2026 (USD Million)
11 Competitive Landscape
11.1 Introduction
Figure 38 Key Developments by Major Players Between January 2017 and July 2021
11.2 Competitive Benchmarking
11.2.1 End-User Footprint of Companies
11.2.2 Product Footprint of Companies
11.2.3 Regional Footprint of Companies
11.3 Real-World Evidence Solutions Market: R&D Expenditure
Figure 39 R&D Expenditure of Key Players in the Real-World Evidence Solutions Market (2019 vs. 2020)
11.4 Revenue Analysis of Key Market Players
Figure 40 Real-World Evidence Solutions Market: Revenue Analysis of Key Market Players (2020)
11.5 Competitive Leadership Mapping
11.5.1 Stars
11.5.2 Emerging Leaders
11.5.3 Pervasive Players
11.5.4 Emerging Companies
Figure 41 Competitive Leadership Mapping: Real-World Evidence Solutions Market, 2020
11.6 Competitive Leadership Mapping - Start-Ups/SMEs
11.6.1 Progressive Companies
11.6.2 Starting Blocks
11.6.3 Responsive Companies
11.6.4 Dynamic Companies
Figure 42 Competitive Leadership Mapping for Start-Ups/SMEs
11.7 Market Ranking Analysis
Figure 43 Real-World Evidence Solutions Market Ranking Analysis, by Key Player, 2020
11.8 Competitive Situation and Trends
11.8.1 Solution Launches
11.8.2 Deals
11.8.3 Other Developments
12 Company Profiles
12.1 Key Players
(Business Overview, Solutions/Services Offered, Recent Developments, and Analyst's View)*
12.1.1 IQVIA
Table 114 IQVIA: Business Overview
Figure 44 IQVIA: Company Snapshot (2020)
12.1.2 IBM
Table 115 IBM Corporation: Business Overview
Figure 45 IBM Corporation: Company Snapshot (2020)
12.1.3 Optum (a Subsidiary of the United Health Group, Inc.)
Table 116 Optum, Inc: Business Overview
Figure 46 Optum: Company Snapshot (2020)
12.1.4 Pharmaceutical Product Development, LLC
Table 117 PPD: Business Overview
Figure 47 PPD: Company Snapshot (2020)
12.1.5 PAREXEL International Corporation
Table 118 PAREXEL International Corporation: Business Overview
12.1.6 PerkinElmer
Table 119 PerkinElmer: Business Overview
Figure 48 PerkinElmer: Company Snapshot (2020)
12.1.7 ICON plc
Table 120 ICON plc: Business Overview
Figure 49 ICON plc: Company Snapshot (2020)
12.1.8 Oracle
Table 121 Oracle: Business Overview
Figure 50 Oracle: Company Snapshot (2020)
12.1.9 Cognizant
Table 122 Cognizant: Business Overview
Figure 51 Cognizant: Company Snapshot (2020)
12.1.10 Syneos Health
Table 123 Syneos Health: Business Overview
Figure 52 Syneos Health: Company Snapshot (2020)
12.1.11 Anthem
Table 124 Anthem, Inc.: Business Overview
Figure 53 Anthem, Inc.: Company Snapshot (2020)
12.1.12 Clinigen
Table 125 Clinigen: Business Overview
Figure 54 Clinigen: Company Snapshot (2020)
12.1.13 SAS Institute
Table 126 SAS Institute: Business Overview
Figure 55 SAS Institute: Company Snapshot (2020)
12.1.14 Cerner Corporation
Table 127 Cerner Corporation: Business Overview
Figure 56 Cerner Corporation: Company Snapshot (2020)
12.1.15 Cegedim Health Data
Table 128 Cegedim Health Data: Business Overview
12.1.16 Aetion
Table 129 Aetion: Business Overview
12.1.17 TriNetX
Table 130 TriNetX: Business Overview
12.1.18 Trinity
Table 131 Trinity: Business Overview
12.1.19 Verantos
Table 132 Verantos: Business Overview
12.1.20 Medpace Holdings
Table 133 Medpace Holdings: Business Overview
Figure 57 Medpace Holdings: Company Snapshot (2020)
*Business Overview, Solutions/Services Offered, Recent Developments, and Analyst's View Might Not be Captured in Case of Unlisted Companies
12.2 Other Players
12.2.1 Syapse
12.2.2 Ciox Health
12.2.3 Tempus
12.2.4 Flatiron Health
12.2.5 Sciformix
13 Appendix
13.1 Discussion Guide
13.2 Knowledge Store: The Subscription Portal
13.3 Available Customizations
Note: Product cover images may vary from those shown
  • Aetion
  • Anthem
  • Cegedim Health Data
  • Cerner Corporation
  • Ciox Health
  • Clinigen
  • Cognizant
  • Flatiron Health
  • IBM
  • ICON plc
  • IQVIA
  • Medpace Holdings
  • Optum (a Subsidiary of the United Health Group, Inc.)
  • Oracle
  • PAREXEL International Corporation
  • Perkinelmer
  • Pharmaceutical Product Development, LLC
  • SAS Institute
  • Sciformix
  • Syapse
  • Syneos Health
  • Tempus
  • TriNetX
  • Trinity
  • Verantos
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll